The University of Oxford announces it has dosed the first patients in a phase I study of NUC-7738

The Oxford Early Phase Clinical Trials Unit (EPCTU) announced that it has dosed the first cancer patients to receive NUC-7738. The clinical study NuTide:701 is a 2-part Phase I dose-escalation study in patients with advanced solid tumours. NUC 7738 is the third ProTide to enter the clinic from NuCana (NASDAQ: NCNA), a biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer.

NUC-7738 is a ProTide transformation of cordycepin or 3’-deoxyadenosine, a novel nucleoside analog isolated from the fungus Cordyceps sinensis in 1950, that has demonstrated potent anti-cancer activity in multiple non-clinical studies. As with NuCana’s other ProTides, NUC-7738 is designed to generate significantly higher levels of the active anti-cancer metabolite directly inside cells, bypassing the resistance mechanisms of transport, activation and breakdown.

Sarah Blagden, Associate Professor of Experimental Cancer Therapeutics at The University of Oxford and Principal Investigator of the NuTide:701 study stated: “We are particularly proud of this study as our own scientists continue to work on understanding of the mechanism of action of this exciting new agent. The application of NuCana’s ProTide chemistry, has created this new chemical entity and we look forward to seeing the results in patients” More information regarding this study can be found here.

Find out more about Oxford’s clinical trials below: